Melatonin in complex treatment for colorectal cancer patients

Published on Friday, 23 November 2018


Colorectal cancer is closely related to changes in the immune status at all stages of the disease.

The main method of treatment for colorectal cancer is surgery.

Surgical intervention as any pathological impact on the body from the outside is leading to suppression of both humoral and cellular immunity.

Melatonin can be used to stimulate the immune system acting as a protective agent.

Currently melatonin is used in oncology practice rather modest - as part of a complex postoperative therapy.

Melatonin in pharmaceutical concentrations acts as differentiation factor reducing infiltrative and metastatic potential by restoring the links between signaling molecules and inhibiting existing cell-cell contacts, which can be used in the preoperative therapy.


About this publication.

See also:

- Official Web Site: The Di Bella Method;

- About Melatonin - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.